A phase I/II study of dasatinib in relapsed or refractory non-Hodgkin's lymphoma (NHL) (BMS [Bristol-Myers Squibb] protocol 180129).
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 15 Aug 2017 Planned End Date changed from 1 Sep 2015 to 1 May 2018.
- 15 Aug 2017 Planned primary completion date changed from 1 Sep 2015 to 1 Apr 2018.
- 07 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.